CIBC Private Wealth Group LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,415 shares of the biopharmaceutical company’s stock after buying an additional 18,894 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Gilead Sciences were worth $14,480,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of GILD. Amundi Pioneer Asset Management Inc. grew its position in Gilead Sciences by 53.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 9,054,685 shares of the biopharmaceutical company’s stock worth $648,679,000 after buying an additional 3,148,128 shares in the last quarter. Point72 Asset Management L.P. grew its position in Gilead Sciences by 147.9% during the first quarter. Point72 Asset Management L.P. now owns 3,078,566 shares of the biopharmaceutical company’s stock worth $232,093,000 after buying an additional 1,836,662 shares in the last quarter. Farallon Capital Management LLC acquired a new stake in Gilead Sciences during the first quarter worth approximately $137,210,000. State Treasurer State of Michigan grew its position in Gilead Sciences by 55.5% during the first quarter. State Treasurer State of Michigan now owns 4,210,424 shares of the biopharmaceutical company’s stock worth $317,424,000 after buying an additional 1,502,700 shares in the last quarter. Finally, BlackRock Inc. grew its position in Gilead Sciences by 1.4% during the first quarter. BlackRock Inc. now owns 105,236,053 shares of the biopharmaceutical company’s stock worth $7,933,746,000 after buying an additional 1,438,806 shares in the last quarter. 77.59% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total value of $3,892,500.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $238,825,271.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 150,000 shares of company stock valued at $10,839,500 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

A number of equities research analysts recently issued reports on the company. BidaskClub downgraded Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 20th. Mizuho set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, July 31st. ValuEngine downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, June 27th. Barclays reduced their price target on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. Finally, Leerink Swann set a $72.00 price target on Gilead Sciences and gave the stock a “market perform” rating in a research report on Wednesday, May 2nd. Twelve research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $88.00.

Gilead Sciences opened at $78.04 on Friday, according to MarketBeat.com. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 3.23. Gilead Sciences, Inc. has a fifty-two week low of $64.27 and a fifty-two week high of $89.54. The firm has a market cap of $101.61 billion, a price-to-earnings ratio of 9.12, a price-to-earnings-growth ratio of -5.97 and a beta of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The firm had revenue of $5.65 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the company earned $2.56 earnings per share. The company’s quarterly revenue was down 20.9% on a year-over-year basis. analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 27th. Shareholders of record on Friday, September 14th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 2.92%. The ex-dividend date is Thursday, September 13th. Gilead Sciences’s payout ratio is presently 26.64%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: What is a closed-end mutual fund (CEF)?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.